KOD
$41.35
+$1.37 (3.43%)+3.43%
ClosedLoading chart...
IndexN/A
Market Cap2.59B
Enterprise Value1.44B
Income$-0.06B
Sales$0.00B
EmployeesN/A
P/E-9.92
P/S0.00
P/B9.45
P/C-10.90
EV/EBITDA-7.06
EV/SalesN/A
EPS (ttm)-4.17
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume0.74M
Shs Outstand0.06B
Change3.43%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $26.71M | $25.95M | $11.00M | $8.71M | $4.21M | $911.00K | $490.00K | $549.00K |
| Gross Profit | $-26.71M | $-25.95M | $-11.00M | $-8.71M | $-4.21M | $-911.00K | $-490.00K | $-549.00K |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Expenses | $160.14M | $251.37M | $330.38M | $258.34M | $131.80M | $48.28M | $25.88M | $24.97M |
| Operating Income | $-186.85M | $-277.32M | $-341.38M | $-267.05M | $-136.01M | $-49.19M | $-26.37M | $-25.52M |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | $-176.21M | $-260.49M | $-333.82M | $-266.99M | $-133.10M | $-47.37M | $-41.44M | $-27.94M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS (Basic) | $-3.35 | $-4.97 | $-6.39 | $-5.16 | $-2.91 | $-1.23 | $-1.16 | $-1.05 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $335.58M | $479.37M | $666.63M | $904.22M | $1.07B | $358.87M | $92.19M | $3.24M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $185.29M | $213.59M | $230.46M | $240.90M | $206.60M | $13.51M | $5.36M | $71.98M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $150.29M | $265.78M | $436.17M | $663.32M | $860.75M | $345.36M | $86.83M | $-68.74M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $150.29M | $265.78M | $436.17M | $663.32M | $860.75M | $345.36M | $86.83M | $-68.74M |
| Total Liabilities & Stockholders Equity | $335.58M | $479.37M | $666.63M | $904.22M | $1.07B | $358.87M | $92.19M | $3.24M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-176.21M | $-260.49M | $-333.82M | $-266.99M | $-133.10M | $-47.37M | $-41.44M | $-27.94M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-117.32M | $-154.18M | $-206.46M | $-182.27M | $-83.43M | $-39.15M | $-29.03M | $-17.66M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Diabetic Retinopathy Pipeline Insight 2026: Comprehensive Analysis of 50+ Companies and 55+ Drugs in DevelopmentGlobeNewswire Inc. Russell 2000 Rips To Record High — Here Are The Top Small Cap GainersBenzinga Ameresco, Lithium Americas, Kodiak Sciences And Other Big Stocks Moving Higher On ThursdayBenzinga Diabetic Retinopathy Global Clinical Trials Review 2024: Region, country (G7 & E7), phase, trial status, End-points Status and Sponsor TypeGlobeNewswire Inc. Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?Zacks Investment Research Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?Zacks Investment Research Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in FocusZacks Investment Research Kodiak (KOD) Counts on Tarcocimab Program Despite SetbacksZacks Investment Research
Show 12 more stories
Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in FocusZacks Investment Research Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in FocusZacks Investment Research Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionBenzinga US Stocks Flat; Initial Jobless Claims Fall To 210,000Benzinga Merck (MRK) Unit to Buy Elanco's Aqua Business for $1.3BZacks Investment Research Vertex's (VRTX) Q4 Earnings and Sales Surpass EstimatesZacks Investment Research TEVA Q4 Earnings and Revenues Surpass Estimates, Stock UpZacks Investment Research Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug AduhelmZacks Investment Research Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day SessionBenzinga EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease DataZacks Investment Research
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Discover more
You may be interested in